The WHI Randomized Trials: Is Menopausal Hormone Therapy Associated with Long-Term Mortality?
PURPOSE:
The original WHI trials were designed to assess risk vs benefits of menopausal hormone therapy
Double-blinded, placebo-controlled, randomized clinical trials, conducted among US postmenopausal women aged 50 to 79 years at enrollment using the following 2 drug regimens
Conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) for women with an intact uterus
CEE alone for women with hysterectomy
The CEE plus MPA trial was stopped early (after 5.6 years) due to an increased risk of breast cancer and overall risks exceeding benefits
CEE-alone trial was stopped after 7.2 years due to an increased risk of stroke
Postintervention follow up has been ongoing
Manson et al. (JAMA, 2017) report the extended follow up on all-cause and cause-specific mortality with attention to age
METHODS:
Postintervention follow up study of the two WHI studies (1993-1998)
Total 27,347 postmenopausal women ages 50 to 79 years were recruited at 40 US clinical centers
16,608 women with a uterus received daily oral CEE (0.625 mg) plus MPA (2.5 mg) or placebo
10,739 women with hysterectomy received daily oral CEE (0.625 mg) alone or placebo
Primary outcome: All-cause mortality
Cause-specific mortality (cardiovascular disease cancer and other major causes)
18 year follow up in 2 trials separately and combined (pooled)
RESULTS:
All-cause mortality
Pooled cohort: 27.1% in the hormone therapy group vs 27.6% in the placebo group (hazard ratio [HR], 0.99 [95% CI, 0.94-1.03])
CEE plus MPA: HR 1.02 (95% CI, 0.96-1.08)
CEE alone: HR 0.94 (95% CI, 0.88-1.01)
Cardiovascular mortality
Pooled cohort: HR 1.00 (95% CI, 0.92-1.08)
Total cancer mortality
Pooled cohort: HR 1.03 (95% CI, 0.95-1.12)
Other causes
Pooled cohort: HR 0.95 (95% CI, 0.88-1.02)
results did not differ significantly between trials
Comparing younger women (50-59 years) to older women (70-79 years) in the pooled cohort for all-cause mortality
During intervention phase: all-cause mortality reduced compared to older women
ratios of HRs 0.61 (95% CI, 0.43-0.87)
During cumulative 18-year follow-up: no difference seen in all-cause mortality compared to older women
ratios of HRs 0.87 (95% CI, 0.76-1.00)
No significant difference between trials
CONCLUSION:
There was no long-term association between hormone replacement and all-cause or cause-specific mortality during a follow up period of 18 years in women who used combination estrogen plus progestin for 5.6 or estrogen-alone group for 7.2 years
Limitations include specific hormone replacement formulations and therefore results may not be generalizable
Cause-specific mortality results should be considered exploratory because multiple smaller subgroups were analyzed
The accompanying editorial states that this present study supports the recently released 2017 NAMS guidance and women should be reassured and hormone therapy appears “safe and efficacious”.
North American Menopause Society: Hormone Therapy Statement
SUMMARY:
NAMS updated its position statement on hormone therapy (2017), based on an extensive literature review. Hormone therapy (HT) is the most effective treatment for vasomotor symptoms (VMS; hot flashes, night sweats) and genitourinary syndrome of menopause (GSM).
Prior estrogen-sensitive breast or endometrial cancer
Coronary heart disease
Stroke
Dementia
Personal history/inherited high risk of thromboembolism
Other: porphyria cutanea tarda, hypertriglyceridemia, endometriosis/leiomyoma with concern for worsening symptoms or growth
POTENTIAL RISKS OF HT
Women < 60 years or who are within 10 years of menopause
Breast cancer (rare risk) with combined estrogen-progestogen therapy
Endometrial hyperplasia and cancer with unopposed estrogen
VTE
Biliary issues
Women across the age spectrum
MI
Stroke
Dementia
FDA APPROVED INDICATIONS FOR HT
(Level I: Based on good and consistent scientific evidence / Level II: Based on limited or inconsistent scientific evidence / Level III: Based primarily on consensus and expert opinion)
Bothersome vasomotor symptoms (Level I)
Prevention of bone loss (Level I)
Hypoestrogenism caused by hypogonadism, surgical castration or premature ovarian insufficiency (Level II)
Genitourinary symptoms (Level I)
NAMS RECOMMENDATIONS FOR TYPE / REGIMEN / DURATION OF USE
Individualize type, dose & regimen
For women with a uterus and using systematic estrogen, ensure endometrial protection (Level I)
Use adequate dose and duration of a progestogen
In WHI, addition of medroxyprogesterone acetate 2.5 mg daily resulted in same risk of endometrial cancer as placebo (hazard ratio 0.81 (95% CI 0.48-1.36)
combine conjugated equine estrogens (CEE) with bazedoxifene
Progestogen therapy not recommended for low-dose vaginal ET (Level I)
Evaluate endometrium if bleeding does occur
Lower doses/transdermal HT may be appropriate in women with metabolic syndrome that include hypertriglyceridemia / risk of pancreatitis / fatty liver (Level III)
Avoid compounded bioidentical HT given concerns about safety (Level I)
Do not use salivary hormone testing to dictate dosing
Individualize duration
Premature menopause, either natural or induced < age 45 and especially if < age 40
Continue HT at least until age 52, which is the median age of menopause (Level II)
The recommendation to routinely discontinue HT in women aged 65 and older is not supported by data
Decision to continue > 60 years of age includes quality of life, VMS, bone loss/fracture and other medical risks vs benefits (Level III)
NAMS RECOMMENDATIONS FOR SPECIAL POPULATIONS AND CANCER RISK
Family history of breast cancer
Use of HT does not appear to increase risk (Level II)
Family history is a risk factor for breast cancer and should be assessed when counseling about HT
BRCA positive without breast cancer
For BRCA positive women who have undergone prophylactic oophorectomy, risks due to premature loss of estrogen need to be considered (Level II)
Limited observational studies suggest HT until age 52, then individualize (Level II)
Ovarian Cancer
Data does not support estrogen as an initiator or promotor of epithelial ovarian cancer
In WHI, no increased risk of ovarian cancer with CEE + medroxyprogesterone acetate (5.6 years’ therapy with 13 years follow-up)
If association between HT and ovarian cancer exists, absolute risk likely to be rare (<1/1,000) or very rare (<0.01/1,000) and related to duration of use
Limited data has not demonstrated increased risk in women with family history of ovarian cancer or BRCA mutation carriers who use estrogen-progestogen therapy
Observational data inconsistent with some (not all studies) demonstrating increased risk after 5 to 10 years
Data limited on ER+ tumors such as low-grade serous carcinomas and sex cord stromal malignancies
Breast and endometrial cancer survivors: Systemic HT for VMS
Encourage nonhormonal therapies (Level III)
Endometrial cancer survivor
If VMS not well controlled, may consider HT in conjunction with oncologist (Level III)
Breast cancer survivor (especially ER+)
Systemic HT should not be offered but if other nonhormonal alternatives have failed, shared decision making that includes an oncologist can be considered
Breast and endometrial cancer survivors: Low-dose vaginal ET
Low-dose vaginal ET has minimal systematic absorption and appears to hold minimal to no risk for breast or endometrial cancer (Level II)
Endometrial cancer survivor following hysterectomy and successful treatment
Consider low-dose vaginal ET in nonhormonal options are unsuccessful (Level II)
Breast cancer survivors
Decisions regarding low-dose vaginal estrogen should involve the treating oncologist especially if patient is on aromatase inhibitors (Level III)
HORMONAL THERAPY DOSAGE/REGIMENS
NOTE: For women with a uterus and using systematic estrogen, ensure endometrial protection with an adequate dose of a progestogen
VSM – systemic
Note:
Standard Dose
Conjugated estrogen 0.625 mg/d
Micronized estradiol-17β 1 mg/d
Transdermal estradiol-17β 0.0375–0.05 mg/d
Low Dose
Conjugated estrogen 0.3–0.45 mg/d
Micronized estradiol-17β 0.5 mg/d
Transdermal estradiol-17β 0.025 mg/d
CEE + SERM
Conjugated estrogen 0.45 mg/d and bazedoxifene 20 mg/d
19-nortestosterone derivative synthetic steroid
Tibolone 2.5 mg/d
Progestin
Not recommended as first line therapy due to safety concerns related to breast cancer risk
Depot medroxyprogesterone acetate 400 mg demonstrated to improve VSM symptoms in RCT
Not FDA approved for this indication
Combined estradiol and progesterone capsules
1 capsule (1 mg/100 mg) /d
Bioidentical therapy
Molecularly identical to circulating hormones (see ‘Related ObG Topics’ below)
GSM – systemic
Standard Dose
Conjugated estrogen 0.625 mg/d
Micronized estradiol-17β 1 mg/d
Transdermal estradiol-17β 0.0375–0.05 mg/d
Low Dose
Conjugated estrogen 0.3–0.45 mg/d
Micronized estradiol-17β 0.5 mg/d
Transdermal estradiol-17β 0.025 mg/d
PROGESTOGENS FOR UTERINE PROTECTION – when using standard dose estrogen
Medroxyprogesterone acetate
2.5 mg po daily for continuous therapy
5 mg daily po with sequential therapy for 12 – 14 days sequentially per 28-day cycle (start day 1 or 16)
Micronized progesterone
100 mg po daily for continuous therapy
200 mg po nightly for 12 days sequentially per 28-day cycle
Formulated with peanut oil – do not use in women with peanut allergies
May cause hypnotic effects and should be taken at bedtime
GSM – local (vaginal, and in the case of creams may also be applied to vestibular area)
Estradiol-17β ring (releases 7.5 micrograms/d): replace every 3 months
Estradiol vaginal tablet (10 micrograms/d): place nightly for 2 weeks
Maintenance is one tablet 2 times/week
Note: this is the corrected dose in ACOG PB 141
Estradiol-17β cream (0.1 mg active ingredient/g): 2-4 g/d for 1 to 2 weeks
Gradually reduce to ½ initial dosage for 1 – 2 weeks
Maintenance is 1 g, 1 to 3 times/week
Conjugated estrogen cream (0.625 mg/g): 0.5–2 g/d for 21 days then off for 7 days
In practice during maintenance therapy, most women apply 1 – 3 times /week
Vaginal inserts (4-μg and 10-μg)
1 vaginal insert daily for 2 weeks
Maintenance is 1 insert twice weekly
KEY POINTS:
Risks of HT differ depending on type/dose/duration/route/timing of initiation and whether a progestogen is needed
Individualize treatment to maximize benefits/minimize risk
Reassess periodically
Women younger than 60 or within 10 years of menopause without contraindications have a favorable benefit-risk ratio for use of HT in the treatment of VMS and reducing bone loss/fracture for those at increased risk
Longer duration may be more favorable for estrogen therapy alone vs combined estrogen-progestin therapy based on the WHI RCTs
Women who begin HT more than 10 years from menopause onset or aged 60 or older have a less favorable benefit-risk ratio, with greater absolute risks of CHD, stroke, thrombosis and dementia
Low-dose vaginal estrogen therapy is recommended for GSM symptoms not relieved with other therapies
The USPSTF Guidance on the Role of Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women (December 2017)
The USPSTF assessed the evidence for harms and benefits for chronic disorders such as coronary heart disease, dementia, stroke, fractures, and breast cancer
The magnitude of both the benefits and the harms of hormone therapy in postmenopausal women is small to moderate
The USPSTF concludes with moderate certainty that there is no net benefit in the use of hormone therapy
The USPSTF recommends against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal women. (*D recommendation)
The USPSTF recommends against the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal women who have had a hysterectomy (*D recommendation)
*D recommendation Suggestion for Practice: Discourage the Use of This Service
Prasterone for Vulvovaginal Atrophy – What is it and How to Prescribe
CLINICAL ACTIONS:
Vulvovaginal atrophy is a common symptom of atrophic vaginitis (also referred to as the genitourinary syndrome of menopause or GSM) and can occur in both perimenopausal and postmenopausal women. If a patient reports vaginal dryness consider the following:
Confirm diagnosis of postmenopausal atrophy through vaginal exam
Discuss use of vaginal estrogen as an option
If patient is not an appropriate candidate for local estrogen or if patient would prefer not to use a direct estrogen product, prasterone may be an effective alternative
One vaginal insert (6.5 mg of prasterone) each evening at bedtime
SYNOPSIS:
Prasterone is an approved, steroid-based FDA treatment for postmenopausal vaginal atrophy. Use is appropriate for women who complain of dyspareunia, or general discomfort due to dryness and thinning of the vaginal mucosa.
KEY POINTS:
During perimenopause and menopause, estrogen levels decline in vaginal tissues and is referred to as vulvovaginal atrophy (VVA), which may result in discomfort or pain during intercourse
Local estrogen can be considered a first line treatment of VVA but may not be appropriate or desired by all patients
The FDA approved prasterone to treat women experiencing moderate to severe dyspareunia, a symptom of VVA, due to menopause
Prasterone is the first FDA approved product containing the synthetic active ingredient dehydroepiandrosterone (DHEA)
DHEA can convert to androgens and/or estrogens and, while the likelihood is low and the quantities minimal, a physician should disclose the following
Based on the fact that there is minimal data on safety in the setting of hormonally sensitive malignancy, the FDA warns against using prasterone if there is a history of or known or suspected breast cancer
Unexplained uterine bleeding is a contraindication to use
It is indicated for use only in postmenopausal women
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan
One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst
You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site